Key Takeaways Sarepta reported a Q4 loss of $3.58 per share as Elevidys sales plunged over 71% year over year.SRPT revenues fell 33% to $442.9M, but still beat estimates on higher collaboration income.Sarepta guided 2026 net product revenues of $1.2B-$1.4B and targets $800M-$900M in expenses.Sarepta Therapeutics, Inc. (SRPT) reported a fourth-quarter 2025 adjusted loss of $3.58 per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. This higher-than-anticipated loss was attributed to an in ...

For the quarter ended December 2025, Zai Lab Limited Unsponsored ADR (ZLAB) reported revenue of $127.6 million, up 17% over the same period last year. EPS came in at -$0.46, compared to -$0.80 in the year-ago quarter.The reported revenue represents a surprise of +6.85% over the Zacks Consensus Estimate of $119.42 million. With the consensus EPS estimate being -$0.44, the EPS surprise was -4.55%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...

Immuneering (NasdaqGM:IMRX) FY Conference February 26, 2026 10:00 AM ET Company ParticipantsBen Zeskind - Co-Founder and CEOConference Call ParticipantsJay Olson - Biotechnology Equity Research AnalystJay OlsonHello, everyone, and welcome to Oppenheimer's 36th Annual Healthcare Life Sciences Conference. I'm Jay Olson, one of the biotech analysts here at Oppenheimer, and it's a pleasure to welcome you to our discussion with Immuneering, and it's an honor to introduce Ben Zeskind, CEO and Co-founder of Immune ...

In Q&A, Massey referenced prior company estimates that seronegative MG could expand the addressable population by about 11,000 patients and ocular MG by about 7,000 patients, noting the ocular figure represented those believed eligible for VYVGART based on market research rather than the entire ocular MG population.Chief Operating Officer Karen Massey said the company views the ADAPT OCULUS results as a “meaningful opportunity” to broaden VYVGART’s reach in MG alongside progress in seronegative MG. She reit ...

Profitability improved in the quarter, with GAAP gross margin rising to 63% from 56% a year earlier, reflecting a more favorable mix and higher volumes that improved manufacturing throughput and productivity. Operating expenses were $18.5 million , up from $17.8 million , with SG&A increasing on higher sales and marketing spending tied primarily to Integrity growth, while R&D held flat at $6.5 million .OEM channel revenue was $17.3 million , down 12% year-over-year. Management pointed to lower year-over-yea ...

Key Takeaways RVMD reported a Q4 2025 loss of $1.86 per share, wider than estimates, with no revenues.Revolution Medicines expects 2026 operating expenses of $1.6B-$1.7B, including stock-based pay.Revolution Medicines advanced daraxonrasib into multiple late-stage studies in PDAC and NSCLC.Revolution Medicines (RVMD) reported a fourth-quarter 2025 loss of $1.86 per share, wider than the Zacks Consensus Estimate of a loss of $1.56. The company had incurred a loss of $1.12 in the year-ago quarter.Currently, R ...

Core Viewpoint - Gossamer Bio (GOSS) has experienced a significant decline of 85.1% over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - GOSS has an RSI reading of 13.04, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Indicators - Analysts covering GOSS have raised earnings estimates for the current year, resulting in an 8.6% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7]. - GOSS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- [Robbins LLP] reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focu ...

Pharvaris (NasdaqGS:PHVS) FY Conference February 26, 2026 09:20 AM ET Company ParticipantsBerndt Modig - CEOMaggie Beller - Executive Director and Head of Corporate and Investor CommunicationsConference Call ParticipantsJeff Jones - Managing Director and Senior Analyst of BiotechnologyJeff JonesMorning, everyone, and welcome back to Oppenheimer's Healthcare Conference. I'm Jeff Jones, one of the analysts on the biotech team, and I'm delighted to welcome this morning, Berndt Modig, CEO of Pharvaris, as well ...

The upcoming report from Xeris Biopharma (XERS) is expected to reveal quarterly earnings of $0.03 per share, indicating an increase of 200% compared to the year-ago period. Analysts forecast revenues of $81.43 million, representing an increase of 35.5% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings release, it ...